Pharming Group | Sustainability Performance
Pharming Group is involved in developing innovative biopharmaceutical products for rare diseases. The company emphasizes research and development aimed at addressing unmet medical needs through effective therapies and treatments.
1988
Netherlands
1,001 - 5,000 employees
Biotechnology
$100M - 500M in revenue
$1M - 10M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9890
Overallⓘ#197
in Netherlandsⓘ#218
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Digital emissions
Controversy level
- Pharming's Ruconest (C1 inhibitor) treatment faced FDA scrutiny over manufacturing quality control at its plasma fractionation facility.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.